Search

Your search keyword '"Hemmelder, M. H."' showing total 18 results
Start Over Author "Hemmelder, M. H." Publication Year Range Last 10 years
18 results on '"Hemmelder, M. H."'

1. De oudere met nierschade

Author

Joosten, J. M. H., Hemmelder, M. H., Kooman, J. P., Muris, J.W.M., editor, Schols, J.M.G.A., editor, Collet, J., editor, and Janssen, D.J.A., editor

Published
2023
Full Text
View/download PDF

3. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Published
2022
Full Text
View/download PDF

4. Differences in mental health status during the COVID-19 pandemic between patients undergoing in-center hemodialysis and peritoneal dialysis.

Author

Bouwmans, Pim, Skalli, Zeinab, Vernooij, Robin W. M., Hemmelder, Marc H., Konijn, Wanda S., Lips, Joy, Mulder, Janneke, Bonenkamp, Anna A., van Jaarsveld, Brigit C., Abrahams, Alferso C., the DOMESTICO study group, Abrahams, A. C., Verhaar, M. C., van Jaarsveld, B. C., Dekker, F. W., van Ittersum, F. J., Konijn, W., Hemmelder, M. H., ten Dam, M. A. G. J., and van Eck van der Sluijs, A.

Published
2023
Full Text
View/download PDF

5. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

Author

Hemmelder, M. H., Noordzij, M., Vart, P., Hilbrands, L. B., Jager, K. J., Abrahams, A. C., Arroyo, D., Battaglia, Y., Ekart, R., Mallamaci, F., Malloney, S. -R., Oliveira, J., Rydzewski, A., Sridharan, S., Vogt, L., Duivenvoorden, R., Gansevoort, R. T., Franssen, C. F. M., van der Net, J. B., Essig, M., du Buf-Vereijken, P. W. G., van Ginneken, B., Maas, N., van Jaarsveld, B. C., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Konings, C. J. A. M., Braconnier, P., Weis, D., Gellert, R., Alferes, D. G., Radulescu, D., Zakharova, E. V., Ambuehl, P. M., Guidotti, R., Walker, A., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Majstorovic, G. S., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Liakopoulos, V., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Kuryata, O., Slebe, J. J. P., Abd ElHafeez, S., Kemlin, D., van de Wetering, J., Reinders, M. E. J., Hesselink, D. A., van Gestel, J. K., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Logan, I., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Polyzou Konsta, M. A., Panagoutsos, S., Postorino, A., Cambareri, F., Matceac, I., Nistor, I., Covic, A., Groeneveld, J. H. M., Jousma, J., Diekmann, F., Oppenheimer, F., Blasco, M., Pereira, T. A., dos Santos Junior, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Arenas Jimenez, M. D., Mendoza-Valderrey, A., Martins, A. C., Mateus, C., Alvila, G., Laranjinha, I., Hofstra, J. M., Siezenga, M. A., Franco, A., Castellano, S., Rodriguez-Ferrero, M. L., Manzanos, S. B., Haridian Sosa Barrios, R., Lemahieu, W., Bartelet, K., Dirim, A. B., Demir, E., Sever, M. S., Turkmen, A., Safak, S., Hollander, D. A. M. J., Kerckhoffs, A., Buttner, S., de Vries, A. P. J., Meziyerh, S., van der Helm, D., Mallat, M., Bouwsma, H., Petruliene, K., Verberk, I., van der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Luca, M. D., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Gandolfini, I., Maggiore, U., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., de Fijter, C. W. H., Mongera, N., Pini, S., de Biase, C., van de Logt, A. E., Maas, R., Lebedeva, O., Lopez, V., Reichert, L. J. M., Verhave, J., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., van Kempen, G., van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Lentini, P., den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Sahin, I., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Coca, A., de Arriba, G., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnerlier, A., Wissing, K. M., Dedinska, I., Pessolano, G., Malik, S., Dounousi, E., Papachristou, E., Berger, S. P., Meijer, E., Sanders, J. S. F., Ozyilmaz, A., Ponikvar, J. B., Pernat, A. M., Kovac, D., Arnol, M., Molenaar, F. M., van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Gallieni, M., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Heitink-Ter Braak, N., Nephrology, ACS - Microcirculation, ACS - Diabetes & metabolism, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Clinical sciences, Faculteit Medische Wetenschappen/UMCG, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, APH - Health Behaviors & Chronic Diseases, and Internal Medicine

Subjects
Male, Outcome Assessment, survival, mental health status, COVID-19 Testing, SDG 3 - Good Health and Well-being, Renal Dialysis, functional health status, Outcome Assessment, Health Care, 80 and over, Humans, KIDNEY-TRANSPLANT, AcademicSubjects/MED00340, Aged, Aged, 80 and over, Transplantation, SARS-CoV-2, MORTALITY, COVID-19, Middle Aged, Health Care, Intensive Care Units, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, dialysis, Original Article, Female, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11]
Abstract

Background Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8–6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

Published
2022

6. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation:a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E.J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P.J., Rispens, T., Steenhuis, M., Gansevoort, R. T., Hemmelder, M. H., Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E.J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P.J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Abstract

BACKGROUND: COVID-19 is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD) stages G4-G5, on dialysis or after kidney transplantation (kidney replacement therapy, KRT). SARS-CoV-2 vaccine trials do not elucidate if SARS-CoV-2 vaccination is effective in these patients. Vaccination against other viruses is known to be less effective in kidney patients. Our objective is to assess the efficacy and safety of various types of SARS-CoV-2 vaccinations in patients with CKD stages G4-G5 or on KRT. METHODS: In this national prospective observational cohort study we will follow patients with CKD stages G4-G5 or on KRT (n = 12,000) after SARS-CoV-2 vaccination according to the Dutch vaccination program. Blood will be drawn for antibody response measurements at day 28 and month 6 after completion of vaccination. Patient characteristics and outcomes will be extracted from registration data and questionnaires during 2 years of follow-up. Results will be compared with a control group of non-vaccinated patients. The level of antibody response to vaccination will be assessed in subgroups to predict protection against COVID-19 breakthrough infection. RESULTS: The primary endpoint is efficacy of SARS-CoV-2 vaccination determined as the incidence of COVID-19 after vaccination. Secondary endpoints are the antibody based immune response at 28 days after vaccination, the durability of this response at 6 months after vaccination, mortality and (serious) adverse events. CONCLUSION: This study will fulfil the lack of knowledge on efficacy and safety of SARS-CoV-2 vaccination in patients with CKD stages G4-G5 or on KRT. TRIAL REGISTRATION: The study protocol has been registered in clinicaltrials.gov ( NCT04841785 ). Current knowledge about this subject COVID-19 has devastating impact on patients with CKD stages G4-G5, on dialysis or after kidney transplantation. Effective SARS-CoV-2 vaccination is very important in these vulnerable patient groups.

Published
2022

7. Additional file 2 of Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Abstract

Additional file 2. Questionnaires at 6, 12 and 24 months after vaccination.

Published
2022
Full Text
View/download PDF

8. Additional file 1 of Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Abstract

Additional file 1. Questionnaire at 1 month after vaccination.

Published
2022
Full Text
View/download PDF

9. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

Author

Mitra, S., Jayanti, A., Vart, P., Coca, A., Gallieni, M., Ovrehus, M. A., Midtvedt, K., Abd Elhafeez, S., Gandolfini, I., Buttner, S., Franssen, C. F. M., Hemmelder, M. H., Van Der Net, J. B., Essig, M., Du Buf-Vereijken, P. W. G., Van Ginneken, B., Maas, N., Vogt, L., Van Jaarsveld, B. C., Jager, K. J., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Rydzewski, A., Gellert, R., Oliveira, J., Alferes, D. G., Zakharova, E. V., Ambuehl, P. M., Walker, A., Winzeler, R., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Slebe, J. J. P., Kemlin, D., Van De Wetering, J., Reinders, M. E. J., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Konsta, M. A. P., Panagoutsos, S., Mallamaci, F., Postorino, A., Cambareri, F., Covic, A., Matceac, I., Nistor, I., Cordos, M., Groeneveld, J. H. M., Jousma, J., Marjolijn Van Buren, Diekmann, F., Tiago Assis Pereira, Santos, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Jimenez, M. D. A., Hofstra, J. M., Franco, A., Arroyo, D., Rodriguez-Ferrero, M. L., Manzanos, S. B., Barrios, R. H. S., Avila, G., Laranjinha, I., Mateus, C., Lemahieu, W., Bartelet, K., Dirim, A. B., Sever, M. S., Demir, E., Safak, S., Turkmen, A., Hollander, D. A. M. J., De Vries, A. P. J., Meziyerh, S., Van Der Helm, D., Mallat, M., Bouwsma, H., Sridharan, S., Petruliene, K., Maloney, S. -R., Verberk, I., Van Der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Di Luca, M., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., De Fijter, C. W. H., Mongera, N., Pini, S., De Biase, C., Duivenvoorden, R., Hilbrands, L., Kerckhoffs, A., Van De Logt, A. -E., Maas, R., Lebedeva, O., Lopez, V., Verhave, J., Reichert, L. J. M., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., Van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Battaglia, Y., Lentini, P., Den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnelier, A., Wissing, K. M., De Arriba, G., Dedinska, I., Pessolano, G., Maggiore, U., Malik, S., Papachristou, E., Gansevoort, R. T., Noordzij, M., Berger, S. P., Meijer, E., Ozyilmaz, A., Sanders, J. S. F., Ponikvar, J. B., Arnol, M., Pernat, A. M., Kovac, D., Ekart, R., Abrahams, A. C., Molenaar, F. M., Van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Sabiu, G., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., Van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Braak, N. H. -T., Nephrology, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Groningen Kidney Center (GKC), ACS - Diabetes & metabolism, AII - Inflammatory diseases, AII - Infectious diseases, Internal Medicine, and Clinical sciences

Subjects
kidney, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Pulmonary insufficiency, infectious diseases, Kidney, Second presentation, Interquartile range, Internal medicine, medicine, Humans, Registries, Mortality, AcademicSubjects/MED00340, Dialysis, Aged, Transplantation, second presentation, business.industry, SARS-CoV-2, COVID-19, medicine.disease, mortality, Triage, Hospitalization, Renal Replacement Therapy, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, Oxygen Saturation, dialysis, Original Article, Hemodialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Presentation (obstetrics), business, transplantation
Abstract

Background Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2–7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.

Published
2021

10. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant

Author

Kho, Marcia M. L., Reinders, Marlies E. J., Baan, Carla C., van Baarle, Debbie, Bemelman, Frederike J., DIavatopoulos, D. Imitri A., Gansevoort, Ron T., van der Klis, Fiona R. M., Koopmans, Marion P. G., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Rots, Nynke, Vart, Priya, de Vries, Rory D., Hilbrands, Luuk B., Sanders, Jan-Stephan F., Abrahams, A. C., Hemmelder, M. H., ten Dam, M. A. G. J., de Vries, A. P. J., van Binnendijk, R. S., den Hartog, G., Bouwmans, P., Frolke, S., Malahé, S. R. K., Translational Immunology Groningen (TRIGR), Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Nephrology, AII - Inflammatory diseases, Experimental Immunology, APH - Aging & Later Life, Internal Medicine, and Virology

Subjects
Chronic/complications, medicine.medical_specialty, COVID-19 Vaccines, Renal Insufficiency, Chronic/complications, medicine.medical_treatment, COVID-19/prevention & control, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Kidney Failure, Immune system, SDG 3 - Good Health and Well-being, Renal Dialysis, Internal medicine, Research Letter, medicine, Humans, Renal Insufficiency, Renal Insufficiency, Chronic, AcademicSubjects/MED00340, Vaccines, Synthetic/adverse effects, Dialysis, Kidney transplantation, Vaccines, Transplantation, Vaccines, Synthetic, business.industry, Immunity, COVID-19, medicine.disease, Kidney Transplantation, Chronic/therapy, Vaccination, Kidney Failure, Chronic/therapy, Nephrology, Cohort, Kidney Failure, Chronic, Observational study, Hemodialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, Synthetic/adverse effects, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Kidney disease, 2019-nCoV Vaccine mRNA-1273, COVID-19 Vaccines/adverse effects
Abstract

Contains fulltext : 237509.pdf (Publisher’s version ) (Open Access)

Published
2021

11. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Author

Hilbrands, L. B., Duivenvoorden, R., Vart, P., Franssen, C. F. M., Hemmelder, M. H., Jager, K. J., Kieneker, L. M., Noordzij, M., Pena, M. J., de Vries, H., Arroyo, D., Covic, A., Crespo, M., Goffin, E., Islam, M., Massy, Z. A., Montero, N., Oliveira, J. P., Munoz, A. R., Sanchez, J. E., Sridharan, S., Winzeler, R., Gansevoort, R. T., van der Net, Jeroen B., Marie, Essig, Peggy W, G du Buf-Vereijken, Betty van Ginneken, Nanda, Maas, Liffert, Vogt, van Jaarsveld, Birgit C., Bemelman, Frederike J., Farah, Klingenberg-Salahova, Frederiek, Heenan-Vos, Vervloet, Marc G., Azam, Nurmohamed, Daniel, Abramowicz, Sabine, Verhofstede, Omar, Maoujoud, Jana, Fialova, Edoardo, Melilli, Alex, Favà, Cruzado, Josep M., Joy, Lips, Maaike, Hengst, Ryszard, Gellert, Andrzej, Rydzewski, Alferes, Daniela G., Ivan, Rychlik, Zakharova, Elena V., Patrice Max Ambuehl, Fanny, Lepeytre, Clémentine, Rabaté, Guy, Rostoker, Sofia, Marques, Tijana, Azasevac, Dajana, Katicic, Marc ten Dam, Thilo, Krüger, Susan J, J Logtenberg, Lutz, Fricke, L van Zanen, A, Jeroen J, P Slebe, Delphine, Kemlin, Jacqueline van de Wetering, Jaromir, Eiselt, Lukas, Kielberger, El-Wakil, Hala S., Samar Abd ElHafeez, Christina, Canal, Carme, Facundo, Ramos, Ana M., Alicja, Debska-Slizien, Nicoline M, H Veldhuizen, Stylianos, Panagoutsos, Irina, Matceac, Ionut, Nistor, Monica, Cordos, J H, M Groeneveld, Marjolijn van Buren, Fritz, Diekmann, Ferreira, Ana C., Augusto Cesar, S. Santos Jr., Carlos, Arias-Cabrales, Laura, Llinàs-Mallol, Anna, Buxeda, Carla Burballa Tàrrega, Dolores, Redondo-Pachon, Maria Dolores Arenas Jimenez, Hofstra, Julia M., Antonio, Franco, Rodríguez-Ferrero, María L., Sagrario Balda Manzanos, Gabriel de Arriba, Haridian Sosa Barrios, R., Karlijn, Bartelet, Erol, Demir, Daan A M, J Hollander, Angele, Kerckhoffs, Stefan, Büttner, Aiko P, J de Vries, Soufian, Meziyerh, Danny van der Helm, Marlies, Reinders, Hanneke, Bouwsma, Kristina, Petruliene, Sharon, Maloney, Iris, Verberk, Marina Di Luca, Tuğlular, Serhan Z., Charles, Beerenhout, Luik, Peter T., Julia, Kerschbaum, Martin, Tiefenthaler, Bruno, Watschinger, Adema, Aaltje Y., Stepanov, Vadim A., Zulkarnaev, Alexey B., Kultigin, Turkmen, Bonucchi, Decenzio, Anselm, Fliedner, Hitoshi, Miyasato, Anders, Åsberg, Geir, Mjoen, Stefano, Pini, Consuelo de Biase, Anne Els van de Logt, Rutger, Maas, Olga, Lebedeva, Veronica, Lopez, Louis J, M Reichert, Jacobien, Verhave, Denis, Titov, Parshina, Ekaterina V., Liesbeth E, A van Gils-Verrij, Charlotte J, R de Bruin, Harty, John C., Marleen, Meurs, Marek, Myslak, Yuri, Battaglia, Paolo, Lentini, Edwin den Deurwaarder, Hormat, Rahimzadeh, Marcel, Schouten, Cabezas-Reina, Carlos J., Anabel, Diaz-Mareque, Armando, Coca, Björn K, I Meijers, Maarten, Naesens, Dirk, Kuypers, Bruno, Desschans, Annelies, Tonnerlier, Wissing, Karl M., Ivana, Dedinska, Giuseppina, Pessolano, van der Sande, Frank M., Maarten H, L Christiaans, Ilaria, Gandolfini, Umberto, Maggiore, Nada, Kanaan, Laura, Labriola, Arnaud, Devresse, Shafi, Malik, Berger, Stefan P., Esther, Meijer, Sanders, Jan Stephan F., Jadranka Buturović Ponikvar, Abrahams, Alferso C., Molenaar, Femke M., van Zuilen, Arjan D., S C, A Meijvis, Helma, Dolmans, Luca, Zanoli, Carmelita, Marcantoni, Esposito, Pasquale, Jean-Marie, Krzesinski, Jean Damacène Barahira, Maurizio, Gallieni, Gianmarco, Sabiu, Paloma Leticia Martin-Moreno, Gabriele, Guglielmetti, Gabriella, Guzzo, Luik, Antinus J., Willi H, M van Kuijk, Lonneke W, H Stikkelbroeck, Hermans, Marc M. H., Laurynas, Rimsevicius, Marco, Righetti, Nicole Heitink-ter Braak, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Clinical sciences, Nephrology, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Global Health, and APH - Quality of Care

Subjects
Male, Databases, Factual, Kidney Failure, Chronic/mortality, medicine.medical_treatment, 030232 urology & nephrology, Waiting Lists/mortality, Kidney Failure, 0302 clinical medicine, Risk Factors, Epidemiology, Kidney Transplantation/mortality, 80 and over, Medicine, 030212 general & internal medicine, Prospective Studies, Chronic, Prospective cohort study, Kidney transplantation, Aged, 80 and over, Renal Dialysis/mortality, SARS-CoV-2/isolation & purification, Hazard ratio, Age Factors, Middle Aged, Prognosis, Europe, Survival Rate, Nephrology, COVID-19, Dialysis, Kidney, Mortality, Transplantation, Adult, Aged, Female, Humans, Kidney Failure, Chronic, Kidney Transplantation, Renal Dialysis, SARS-CoV-2, Waiting Lists, Hemodialysis, medicine.medical_specialty, kidney, Europe/epidemiology, 03 medical and health sciences, Databases, All institutes and research themes of the Radboud University Medical Center, Internal medicine, AcademicSubjects/MED00340, Survival rate, Factual, COVID-19/chemically induced, business.industry, Original Articles, medicine.disease, mortality, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], dialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, transplantation
Abstract

Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

Published
2020
Full Text
View/download PDF

12. Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group

Author

Verberne, WR, Das-Gupta, Z, Allegretti, AS, Bart, HAJ, Van Biesen, W, Garcia-Garcia, G, Gibbons, E, Parra, E, Hemmelder, M H, Jager, KJ, Ketteler, M, Roberts, C, Al Rohani, M, Salt, MJ, Stopper, A, Terkivatan, Turkan, Tuttle, KR, Yang, CW, Wheeler, DC, Bos, WJW, Verberne, WR, Das-Gupta, Z, Allegretti, AS, Bart, HAJ, Van Biesen, W, Garcia-Garcia, G, Gibbons, E, Parra, E, Hemmelder, M H, Jager, KJ, Ketteler, M, Roberts, C, Al Rohani, M, Salt, MJ, Stopper, A, Terkivatan, Turkan, Tuttle, KR, Yang, CW, Wheeler, DC, and Bos, WJW

Published
2019

14. Safety and long-term effects of renal denervation : Rationale and design of the Dutch registry

Author

Sanders, M. F., Blankestijn, P. J., Voskuil, M., Spiering, W., Vonken, E. J., Rotmans, J. I., van der Hoeven, B. L., Daemen, J., van den Meiracker, A. H., Kroon, A. A., de Haan, M.W., Das, M., Bax, M., van der Meer, I. M., van Overhagen, H., van den Born, B. J H, van Brussel, P. M., van der Valk, P.H.M., Smak Gregoor, P. J H, Meuwissen, M., Gomes, M. E R, Oude Ophuis, T., Troe, E., Tonino, W. A L, Konings, C. J A M, de Vries, P. A M, van Balen, A., Heeg, J. E., Smit, J. J J, Elvan, A., Steggerda, R., Niamut, S. M L, Peels, J. O J, de Swart, J. B R M, Wardeh, A. J., Groeneveld, J. H M, van der Linden, E., Hemmelder, M. H., Folkeringa, R., Stoel, M. G., Kant, G. D., Herrman, J. P R, van Wissen, S., Deinum, J., Westra, S. W., Aengevaeren, W. R M, Parlevliet, K. J., Schramm, A., Jessurun, G. A J, Rensing, B. J W M, Winkens, M. H M, Wierema, T. K A, Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C. P., Nap, A., Bots, M. L., Sanders, M. F., Blankestijn, P. J., Voskuil, M., Spiering, W., Vonken, E. J., Rotmans, J. I., van der Hoeven, B. L., Daemen, J., van den Meiracker, A. H., Kroon, A. A., de Haan, M.W., Das, M., Bax, M., van der Meer, I. M., van Overhagen, H., van den Born, B. J H, van Brussel, P. M., van der Valk, P.H.M., Smak Gregoor, P. J H, Meuwissen, M., Gomes, M. E R, Oude Ophuis, T., Troe, E., Tonino, W. A L, Konings, C. J A M, de Vries, P. A M, van Balen, A., Heeg, J. E., Smit, J. J J, Elvan, A., Steggerda, R., Niamut, S. M L, Peels, J. O J, de Swart, J. B R M, Wardeh, A. J., Groeneveld, J. H M, van der Linden, E., Hemmelder, M. H., Folkeringa, R., Stoel, M. G., Kant, G. D., Herrman, J. P R, van Wissen, S., Deinum, J., Westra, S. W., Aengevaeren, W. R M, Parlevliet, K. J., Schramm, A., Jessurun, G. A J, Rensing, B. J W M, Winkens, M. H M, Wierema, T. K A, Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C. P., Nap, A., and Bots, M. L.

Published
2016

15. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry

Author

Opleiding Neurologie, MS Nefrologie, Circulatory Health, Cardiologie Arts-onderzoekers, MS Infectieziekten, MS Interne Geneeskunde, MS Radiologie, Other research (not in main researchprogram), Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Sanders, M. F., Blankestijn, P. J., Voskuil, M., Spiering, W., Vonken, E. J., Rotmans, J. I., van der Hoeven, B. L., Daemen, J., van den Meiracker, A. H., Kroon, A. A., de Haan, M.W., Das, M., Bax, M., van der Meer, I. M., van Overhagen, H., van den Born, B. J H, van Brussel, P. M., van der Valk, P.H.M., Smak Gregoor, P. J H, Meuwissen, M., Gomes, M. E R, Oude Ophuis, T., Troe, E., Tonino, W. A L, Konings, C. J A M, de Vries, P. A M, van Balen, A., Heeg, J. E., Smit, J. J J, Elvan, A., Steggerda, R., Niamut, S. M L, Peels, J. O J, de Swart, J. B R M, Wardeh, A. J., Groeneveld, J. H M, van der Linden, E., Hemmelder, M. H., Folkeringa, R., Stoel, M. G., Kant, G. D., Herrman, J. P R, van Wissen, S., Deinum, J., Westra, S. W., Aengevaeren, W. R M, Parlevliet, K. J., Schramm, A., Jessurun, G. A J, Rensing, B. J W M, Winkens, M. H M, Wierema, T. K A, Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C. P., Nap, A., Bots, M. L., Opleiding Neurologie, MS Nefrologie, Circulatory Health, Cardiologie Arts-onderzoekers, MS Infectieziekten, MS Interne Geneeskunde, MS Radiologie, Other research (not in main researchprogram), Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Sanders, M. F., Blankestijn, P. J., Voskuil, M., Spiering, W., Vonken, E. J., Rotmans, J. I., van der Hoeven, B. L., Daemen, J., van den Meiracker, A. H., Kroon, A. A., de Haan, M.W., Das, M., Bax, M., van der Meer, I. M., van Overhagen, H., van den Born, B. J H, van Brussel, P. M., van der Valk, P.H.M., Smak Gregoor, P. J H, Meuwissen, M., Gomes, M. E R, Oude Ophuis, T., Troe, E., Tonino, W. A L, Konings, C. J A M, de Vries, P. A M, van Balen, A., Heeg, J. E., Smit, J. J J, Elvan, A., Steggerda, R., Niamut, S. M L, Peels, J. O J, de Swart, J. B R M, Wardeh, A. J., Groeneveld, J. H M, van der Linden, E., Hemmelder, M. H., Folkeringa, R., Stoel, M. G., Kant, G. D., Herrman, J. P R, van Wissen, S., Deinum, J., Westra, S. W., Aengevaeren, W. R M, Parlevliet, K. J., Schramm, A., Jessurun, G. A J, Rensing, B. J W M, Winkens, M. H M, Wierema, T. K A, Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C. P., Nap, A., and Bots, M. L.

Published
2016

16. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future

Author

Noordzij, Marlies, Meijers, Björn, Gansevoort, Ron T, Covic, Adrian, Duivenvoorden, Raphaël, Hilbrands, Luuk B, Hemmelder, Marc H, Jager, Kitty J, Mjoen, Geir, Nistor, Ionut, Parshina, Ekaterina, Pessolano, Giuseppina, Tuglular, Serhan, Vart, Priya, Zanoli, Luca, Franssen, Casper F M, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and Noordzij M., Meijers B., Gansevoort R. T., Covic A., Duivenvoorden R., Hilbrands L. B., Hemmelder M. H., Jager K. J., Mjoen G., Nistor I., et al.

Subjects
Internal Diseases, Urology, Sağlık Bilimleri, İç Hastalıkları, Clinical Medicine (MED), All institutes and research themes of the Radboud University Medical Center, UROLOGY & NEPHROLOGY, Health Sciences, Klinik Tıp (MED), KIDNEY-TRANSPLANT, guidelines, ÜROLOJİ VE NEFROLOJİ, Transplantation, Internal Medicine Sciences, Science & Technology, hemodialysis, Klinik Tıp, SARS-CoV-2, MORTALITY, Dahili Tıp Bilimleri, centre practices, CLINICAL MEDICINE, Urology & Nephrology, virus transmission, Tıp, DIALYSIS PATIENTS, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nefroloji, Nephrology, ERACODA, Üroloji, Medicine, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Life Sciences & Biomedicine
Abstract

Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave. Methods We analyzed IPC measures taken by hemodialysis centres treating patients presenting with COVID-19 between 1 March 2020 and 31 July 2020 and that completed the European Renal Association COVID-19 Database centre questionnaire. Additionally, we made an inventory of guidelines published in European countries to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dialysis centres. Results Data from 73 dialysis units located in and bordering Europe were analyzed. All participating centres implemented IPC measures to mitigate the impact of SARS-CoV-2 during the first pandemic wave. Measures mentioned most often included triage with questions before entering the dialysis ward, measuring body temperature, hand disinfection, masking for all patients and staff, and personal protective equipment for staff members. These measures were also recommended in most of the 14 guidelines that were identified in the inventory of national guidelines and were also scored as being among the most important measures by the authors of this paper. Heterogeneity existed between centres and national guidelines regarding the minimal distance between dialysis chairs and recommendations regarding isolation and cohorting. Conclusions Although variation existed, measures to prevent transmission of SARS-CoV-2 were relatively similar across centres and national guidelines. Further research is needed to assess causal relationships between measures taken and spread of SARS-CoV-2.

Published
2022

17. Expanding the clinical spectrum of self-limiting, rare Kikuchi disease - A case with overwhelming multi-organ involvement.

Author

Hoogstins HA, Kibbelaar RE, Ubels FL, Hemmelder MH, and Hoogendoorn M

Subjects
Blood Chemical Analysis, Female, Histiocytic Necrotizing Lymphadenitis diagnosis, Humans, Middle Aged, Necrosis etiology, Remission, Spontaneous, Histiocytic Necrotizing Lymphadenitis complications, Liver pathology, Lymphohistiocytosis, Hemophagocytic etiology, Multiple Organ Failure etiology, Nephrotic Syndrome etiology
Abstract

Kikuchi disease is a rare disorder with an unknown pathogenesis and a typically self-limiting natural course in predominantly previously healthy young women. Here we present a 54-year-old woman suffering from an overwhelming presentation of Kikuchi disease, associated with haemophagocytic syndrome, liver cell necrosis and nephrotic syndrome. She recovered fully without immunosuppressive treatment. This case report adds to the already broad clinical spectrum of Kikuchi disease described in literature. Awareness among physicians of the full clinical spectrum of Kikuchi disease and the self-limiting nature of this syndrome leads to a good diagnostic approach and may prevent initiation of longstanding immunosuppressive therapy.

Published
2017

18. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry.

Author

Sanders MF, Blankestijn PJ, Voskuil M, Spiering W, Vonken EJ, Rotmans JI, van der Hoeven BL, Daemen J, van den Meiracker AH, Kroon AA, de Haan MW, Das M, Bax M, van der Meer IM, van Overhagen H, van den Born BJ, van Brussel PM, van der Valk PH, Smak Gregoor PJ, Meuwissen M, Gomes ME, Oude Ophuis T, Troe E, Tonino WA, Konings CJ, de Vries PA, van Balen A, Heeg JE, Smit JJ, Elvan A, Steggerda R, Niamut SM, Peels JO, de Swart JB, Wardeh AJ, Groeneveld JH, van der Linden E, Hemmelder MH, Folkeringa R, Stoel MG, Kant GD, Herrman JP, van Wissen S, Deinum J, Westra SW, Aengevaeren WR, Parlevliet KJ, Schramm A, Jessurun GA, Rensing BJ, Winkens MH, Wierema TK, Santegoets E, Lipsic E, Houwerzijl E, Kater M, Allaart CP, Nap A, and Bots ML

Subjects
Aged, Antihypertensive Agents therapeutic use, Blood Pressure, Female, Humans, Hypertension drug therapy, Male, Middle Aged, Netherlands epidemiology, Preoperative Period, Prospective Studies, Renal Artery innervation, Sympathectomy methods, Time, Treatment Outcome, Hypertension surgery, Registries, Renal Artery surgery, Sympathectomy statistics & numerical data
Abstract

Background: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapy-resistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands., Methods: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up., Results: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently., Conclusion: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results